Association between skeletal muscle mass and quality of life in adults with cancer: a systematic review and meta-analysis

Lauren Hanna, Kay Nguo, Kate Furness, Judi Porter, Catherine E Huggins, Lauren Hanna, Kay Nguo, Kate Furness, Judi Porter, Catherine E Huggins

Abstract

Low skeletal muscle mass is known to be associated with poor morbidity and mortality outcomes in cancer, but evidence of its impact on health-related quality of life (HRQOL) is less established. This systematic review and meta-analysis was performed to investigate the relationship between skeletal muscle mass and HRQOL in adults with cancer. Five databases (Ovid MEDLINE, Embase via Ovid, CINAHL plus, Scopus, and PsycInfo) were systematically searched from 1 January 2007 until 2 September 2020. Studies reporting on the association between measures of skeletal muscle (mass and/or radiodensity) derived from analysis of computed tomography imaging, and a validated measure of HRQOL in adults with cancer, were considered for inclusion. Studies classifying skeletal muscle mass as a categorical variable (low or normal) were combined in a meta-analysis to investigate cross-sectional association with HRQOL. Studies reporting skeletal muscle as a continuous variable were qualitatively synthesized. A total of 14 studies involving 2776 participants were eligible for inclusion. Skeletal muscle mass classified as low or normal was used to dichotomize participants in 10 studies (n = 1375). Five different cut points were used for classification across the 10 studies, with low muscle mass attributed to 58% of participants. Low muscle mass was associated with poorer global HRQOL scores [n = 985 from seven studies, standardized mean difference -0.27, 95% confidence interval (CI) -0.40 to -0.14, P < 0.0001], and poorer physical functioning domain HRQOL scores (n = 507 from five studies, standardized mean difference -0.40, 95% CI -0.74 to -0.05, P = 0.02), but not social, role, emotional, or cognitive functioning domain scores (all P > 0.05). Five studies examined the cross-sectional relationship between HRQOL and skeletal muscle mass as a continuous variable and found little evidence of an association unless non-linear analysis was used. Two studies investigated the relationship between longitudinal changes in both skeletal muscle and HRQOL, reporting that an association exists across several HRQOL domains. Low muscle mass may be associated with lower global and physical functioning HRQOL scores in adults with cancer. The interpretation of this relationship is limited by the varied classification of low muscle mass between studies. There is a need for prospective, longitudinal studies examining the interplay between skeletal muscle mass and HRQOL over time, and data should be made accessible to enable reanalysis according to different cut points. Further research is needed to elucidate the causal pathways between these outcomes.

Keywords: Body composition; Computed tomography; EORTC QLQ-C30; FACT; Oncology; Sarcopenia.

Conflict of interest statement

None declared.

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic review and Meta‐Analysis (PRISMA) flow diagram of study selection.
Figure 2
Figure 2
Meta‐analysis of baseline global HRQOL scores, with participants grouped according to low or normal skeletal muscle mass stores. The five studies in first subgroup reported only univariate data without adjustment for confounding factors. The two studies in the second subgroup reported multivariate data. Cross‐sectional area of skeletal muscle was measured at the third lumbar vertebra (L3) in all but two studies, where L3 measurements were imputed from alternate sites of analysis: third cervical vertebra (C3) in the study by Hua et al. and fourth thoracic vertebra (T4) in 36% of participants in the study by Blauwhoff‐Buskermolen et al. As the choice of cut point used to detect low or normal muscle mass affects the classification of participants, a second forest plot was generated to demonstrate the pooled results of studies grouped by cut point, presented in Appendix S2. ‘Total’ refers to sample size of low or normal skeletal muscle mass groups in each study. CI, confidence interval.
Figure 3
Figure 3
Meta‐analysis of HRQOL physical function domain scores, with participants grouped according to low or normal skeletal muscle mass stores. The four studies in first subgroup reported only univariate data without adjustment for confounding factors. The study in the second subgroup reported multivariate data. Cross‐sectional area of skeletal muscle was measured at the third lumbar vertebra (L3) in all studies excluding Hua et al., where L3 measurements were imputed from analysis of imaging at the third cervical vertebra (C3). As the choice of cut point used to detect low or normal muscle mass affects the classification of participants, a second forest plot was generated to demonstrate the pooled results of studies grouped by cut point, presented in Appendix S2. ‘Total’ refers to sample size of low or normal skeletal muscle mass groups in each study.

References

    1. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539–1547.
    1. Deluche E, Leobon S, Desport JC, Venat‐Bouvet L, Usseglio J, Tubiana‐Mathieu N. Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 2018;26:861–868.
    1. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population‐based study. Lancet Oncol 2008;9:629–635.
    1. Ninomiya G, Fujii T, Yamada S, Yabusaki N, Suzuki K, Iwata N, et al. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: a retrospective cohort study. Int J Surg 2017;39:45–51.
    1. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta‐analysis and systematic review. Eur J Cancer 2016;57:58–67.
    1. Deng H‐Y, Zha P, Peng L, Hou L, Huang K‐L, Li X‐Y. Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta‐analysis. Dis Esophagus 2018;32:1–10.
    1. Chang KV, Chen JD, Wu WT, Huang KC, Hsu CT, Han DS. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: a systematic review and meta‐analysis. Liver Cancer 2018;7:90–103.
    1. Zhang G, Meng S, Li R, Ye J, Zhao L. Clinical significance of sarcopenia in the treatment of patients with primary hepatic malignancies, a systematic review and meta‐analysis. Oncotarget 2017;8:102474–102485.
    1. Tsukioka T, Izumi N, Kyukwang C, Komatsu H, Toda M, Hara K, et al. Loss of muscle mass is a novel predictor of postoperative early recurrence in N2‐positive non‐small‐cell lung cancer. Ann Torac Surg 2018;24:121–126.
    1. Elliott AJ, Doyle LS, Murphy FC, King MS, Guinan VE, Beddy VP, et al. Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer. Ann Surg 2017;266:822–830.
    1. Zhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, et al. Sarcopenia is an independent predictor of severe postoperative complications and long‐term survival after radical gastrectomy for gastric cancer: analysis from a large‐scale cohort. Medicine 2016;95:e3164, 10.1097/MD.0000000000003164
    1. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012;107:931–936.
    1. Weerink LBM, van der Hoorn A, van Leeuwen BL, de Bock GH. Low skeletal muscle mass and postoperative morbidity in surgical oncology: a systematic review and meta‐analysis. J Cachexia Sarcopenia Muscle 2020;11:636–649.
    1. Jung H‐W, Kim JW, Kim J‐Y, Kim S‐W, Yang HK, Lee JW, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 2015;23:687–694.
    1. Aleixo G, Williams G, Nyrop K, Muss H, Shachar S. Muscle composition and outcomes in patients with breast cancer: meta‐analysis and systematic review. Breast Cancer Res Treat 2019;177:569–579.
    1. Shen W, Punyanitya M, Wang Z, Gallagher D, St‐Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross‐sectional image. J Appl Physiol 2004;97:2333–2338.
    1. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf) 2014;210:489–497.
    1. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. App Physiol Nutr Metab 2008;33:997–1006.
    1. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest 1993;11:327–336.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
    1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X‐S, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population‐based registries in 67 countries (CONCORD‐2). Lancet 2015;385:977–1010.
    1. Kaplan RM, Bush JW. Health‐related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982;1:61–80.
    1. Calman KC. Quality of life in cancer patients—an hypothesis. J Med Ethics 1984;10:124–127.
    1. Fallowfield L. Quality of life: a new perspective for cancer patients. Nat Rev Cancer 2002;2:873–879.
    1. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991;67:844–850.
    1. Karimi M, Health BJ. Health‐related quality of life, and quality of life: what is the difference? Pharmacoeconomics 2016;34:645–649.
    1. Bye A, Sjøblom B, Wentzel‐Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, et al. Muscle mass and association to quality of life in non‐small cell lung cancer patients. J Cachexia Sarcopenia Muscle 2017;8:759–767.
    1. Nipp RD, Fuchs G, El‐Jawahri A, Mario J, Troschel FM, Greer JA, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer. Oncologist 2018;23:97–104.
    1. Aversa Z, Costelli P, Muscaritoli M. Cancer‐induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol 2017;9:369–382.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. BMJ 2009;339:b2535.
    1. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5‐fluorouracil‐based chemotherapy toxicity. Clin Cancer Res 2007;13:3264–3268.
    1. The EndNote Team . EndNote. EndNote X9 ed. Philadelphia, PA: Clarivate Analytics; 2013.
    1. Covidence Systematic Review Software. Melbourne, Australia: Veritas Health Innovation. Available at
    1. Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
    1. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (Eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane; 2021. Available from
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. New York: Routledge; 1988.
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557–560.
    1. Evidence Analysis Manual: Steps in the Academy Evidence Analysis Process. Academy of Nutrition and Dietetics; 2016.
    1. Aleixo GFP, Deal AM, Nyrop KA, Muss HB, Damone EM, Williams GR, et al. Association of body composition with function in women with early breast cancer. Breast Cancer Res Treat 2020;181:411–421.
    1. Blauwhoff‐Buskermolen S, Langius JAE, Becker A, Verheul HMW, de van der Schueren MAE. The influence of different muscle mass measurements on the diagnosis of cancer cachexia. J Cachexia Sarcopenia Muscle 2017;8:615–622.
    1. Daly LE, Dolan RD, Power DG, Ní Bhuachalla É, Sim W, Cushen SJ, et al. Determinants of quality of life in patients with incurable cancer. Cancer 2020;126:2872–2882.
    1. Derksen JWG, Kurk SA, Peeters PHM, Dorresteijn B, Jourdan M, van der Velden AMT, et al. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. J Cachexia Sarcopenia Muscle 2020;11:919–928.
    1. Gigic B, Nattenmüller J, Schneider M, Kulu Y, Syrjala KL, Böhm J, et al. The role of CT‐quantified body composition on longitudinal health‐related quality of life in colorectal cancer patients: the Colocare study. Nutrients 2020;12:1247.
    1. Hua X, Liao J‐F, Liu S, Zhang J, Huang H‐Y, Wen W, et al. Low skeletal muscle mass impairs quality of life in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy. Front Nutr 2020;6:195.
    1. Huang D‐D, Ji Y‐B, Zhou D‐L, Li B, Wang S‐L, Chen X‐L, et al. Effect of surgery‐induced acute muscle wasting on postoperative outcomes and quality of life. J Surg Res 2017;218:58–66.
    1. Mitsui Y, Sadahira T, Watanabe T, Araki M, Maruyama Y, Sato R, et al. Correlation between lumbar skeletal muscle size and urinary incontinence after radical prostatectomy. Low Urin Tract Symptoms 2020;12:245–252.
    1. Sheean P, Gomez‐Perez S, Joyce C, Vasilopoulos V, Bartolotta MB, Robinson P, et al. Body composition, serum biomarkers of inflammation and quality of life in clinically stable women with estrogen receptor positive metastatic breast cancer. Nutr Cancer 2019;71:981–991.
    1. Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Birdsell L, et al. The association of nutritional assessment criteria with health‐related quality of life in patients with advanced colorectal carcinoma. Eur J Cancer Care (Engl) 2012;21:505–516.
    1. van Roekel EH, Bours MJL, Te Molder MEM, Breedveld‐Peters JJL, Olde Damink SWM, Schouten LJ, et al. Associations of adipose and muscle tissue parameters at colorectal cancer diagnosis with long‐term health‐related quality of life. Qual Life Res 2017;26:1745–1759.
    1. Wang C, Vainshtein JM, Veksler M, Rabban PE, Sullivan JA, Wang SC, et al. Investigating the clinical significance of body composition changes in patients undergoing chemoradiation for oropharyngeal cancer using analytic morphomics. Springerplus 2016;5:429.
    1. Jung AR, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer. Oral Oncol 2019;95:95–99.
    1. Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease‐specific quality of life module for use in patients with gastric cancer. Eur J Cancer 2001;37:966–971.
    1. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health‐related quality of life in men with prostate cancer. Urology 2000;56:899–905.
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570–579.
    1. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy‐breast quality‐of‐life instrument. J Clin Oncol 1997;15:974–986.
    1. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B. Breast Cancer Res Treat 1999;55:189–199.
    1. Terrell JE, Nanavati KA, Esclamado RM, Bishop JK, Bradford CR, Wolf GT. Head and neck cancer—specific quality of life: instrument validation. Arch Otolaryngol–Head Neck Surg 1997;123:1125–1132.
    1. Hassan SJ, Weymuller EA Jr. Assessment of quality of life in head and neck cancer patients. Head Neck 1993;15:485–496.
    1. The World Health Organization Quality of Life Assessment (WHOQOL) . Development and general psychometric properties. Soc Sci Med 1998;46:1569–1585.
    1. Nattenmueller J, Hoegenauer H, Boehm J, Scherer D, Paskow M, Gigic B, et al. CT‐based compartmental quantification of adipose tissue versus body metrics in colorectal cancer patients. Eur J Radiol 2016;26:4131–4140.
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
    1. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA 2013;310:1591–1600.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–656.
    1. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DSJ, Foulis AK, et al. An inflammation‐based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104:726–734.
    1. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ‐LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ‐C30) for use in lung cancer clinical trials. Eur J Cancer 1994;30:635–642.
    1. Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R, et al. Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci 2001;56:B209–B217.
    1. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006;61:1059–1064.
    1. Morishita S, Tsubaki A, Fu JB, Mitobe Y, Onishi H, Tsuji T. Cancer survivors exhibit a different relationship between muscle strength and health‐related quality of life/fatigue compared to healthy subjects. Eur J Cancer Care (Engl) 2018;27:e12856, 10.1111/ecc.12856
    1. Cešeiko R, Eglītis J, Srebnijs A, Timofejevs M, Purmalis E, Erts R, et al. The impact of maximal strength training on quality of life among women with breast cancer undergoing treatment. Exp Oncol 2019;41:166–172.
    1. McGregor RA, Cameron‐Smith D, Poppitt SD. It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. Longev Healthspan 2014;3:9.
    1. Colloca G, Di Capua B, Bellieni A, Cesari M, Marzetti E, Valentini V, et al. Muscoloskeletal aging, sarcopenia and cancer. J Geriatr Oncol 2019;10:504–509.
    1. Grimby G, Saltin B. The ageing muscle. Clin Physiol 1983;3:209–218.
    1. Argilés JM, Campos N, Lopez‐Pedrosa JM, Rueda R, Rodriguez‐Mañas L. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J Am Med Dir Assoc 2016;17:789–796.
    1. Demling RH. Nutrition, anabolism, and the wound healing process: an overview. Eplasty 2009;9: e9‐e.
    1. Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017;36:49–64.
    1. Bozzetti F. Chemotherapy‐induced sarcopenia. Curr Treat Options Oncol 2020;21:21.
    1. Daly LE, Ni Bhuachalla EB, Power DG, Cushen SJ, James K, Ryan AM. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle 2018;9:315–325.
    1. Wells JC. Ethnic variability in adiposity, thrifty phenotypes and cardiometabolic risk: addressing the full range of ethnicity, including those of mixed ethnicity. Obes Rev 2012;13:14–29.
    1. Hilmi M, Jouinot A, Burns R, Pigneur F, Mounier R, Gondin J, et al. Body composition and sarcopenia: the next‐generation of personalized oncology and pharmacology? Pharmacol Ther 2019;196:135–159.
    1. Bijlsma AY, Meskers CG, Ling CH, Narici M, Kurrle SE, Cameron ID, et al. Defining sarcopenia: the impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohort. Age 2013;35:871–881.
    1. Hopkins JJ, Skubleny D, Bigam DL, Baracos VE, Eurich DT, Sawyer MB. Barriers to the interpretation of body composition in colorectal cancer: a review of the methodological inconsistency and complexity of the CT‐defined body habitus. Ann Surg Oncol 2018;25:1381–1394.
    1. Rutten IJG, Ubachs J, Kruitwagen RFPM, Beets‐Tan RGH, Olde Damink SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle 2017;8:630–638.
    1. Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle 2020;11:366–380.
    1. Musoro ZJ, Hamel J‐F, Ediebah DE, Cocks K, King MT, Groenvold M, et al. Establishing anchor‐based minimally important differences (MID) with the EORTC quality‐of‐life measures: a meta‐analysis protocol. BMJ Open 2018;8:e019117, 10.1136/bmjopen-2017-019117
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019. J Cachexia Sarcopenia Muscle 2019;10:1143–1145.

Source: PubMed

3
订阅